Depo-Provera and Meningioma: A Timeline of FDA Warnings and Studies

The connection between Depo-Provera and meningioma brain tumors did not emerge overnight. It developed over decades through a series of scientific studies, regulatory actions, and — critics argue — manufacturer inaction. This chronological timeline traces the key events from Depo-Provera’s approval through the current litigation, documenting what was known, when it was known, and what Pfizer and the FDA did (or failed to do) in response.

Understanding this timeline is critical for claimants, as it forms the factual backbone of the failure-to-warn claims at the heart of the Depo-Provera meningioma litigation.

1992: FDA Approves Depo-Provera

The FDA approved depot medroxyprogesterone acetate (DMPA) — marketed as Depo-Provera — as an injectable contraceptive in October 1992. Manufactured by Upjohn (later acquired by Pfizer), Depo-Provera was administered as an intramuscular injection every three months.

The approval came after decades of international use and a prolonged FDA review process that included concerns about cancer risk. Early studies had shown that DMPA caused breast tumors in beagle dogs, which delayed FDA approval for years. However, the approved labeling focused on breast cancer risk and did not include any warning about brain tumors or meningiomas.

2004: Depo-SubQ Provera 104 Approved

Pfizer received FDA approval for a subcutaneous formulation — Depo-SubQ Provera 104 — offering a lower dose administered under the skin rather than into muscle. Like the original formulation, no meningioma warning was included.

Early 2000s-2010s: Growing Scientific Evidence

During this period, researchers began publishing studies exploring the relationship between progestins and meningiomas:

• Meningiomas were known to express hormone receptors. Studies established that approximately two-thirds of meningiomas are positive for progesterone receptors, providing a biological mechanism for hormonal drugs to influence tumor growth.
• Case reports emerged. Clinicians published case reports of meningioma patients with histories of progestin use, including DMPA.
• European research accelerated. French researchers began investigating the link between high-dose progestins (particularly cyproterone acetate, another progestin used in Europe) and meningiomas, producing studies that would later inform the Depo-Provera research.

Despite this emerging evidence, Pfizer’s labeling for Depo-Provera remained unchanged regarding meningioma risk.

2018-2020: French Regulatory Action on Progestins

France became the first country to take regulatory action on the progestin-meningioma link:

• The French National Agency for the Safety of Medicines (ANSM) issued warnings about meningioma risk associated with high-dose progestins
• France restricted prescribing of certain progestin drugs and required physicians to screen patients for meningiomas before prescribing
• These actions were based on French epidemiological data showing elevated meningioma rates in progestin users

The French regulatory response highlighted the risk but focused primarily on progestins used in Europe. Depo-Provera, which is more widely used in the United States and developing countries, did not receive the same regulatory scrutiny from the FDA.

2024: The Landmark BMJ Study

The most significant scientific publication in this timeline was the study published in the British Medical Journal (BMJ). This large-scale epidemiological study found:

• Prolonged use of injectable progestins, including DMPA, was associated with a substantially increased risk of intracranial meningioma
• The study demonstrated a dose-response relationship — the longer the exposure to injectable progestins, the higher the risk
• The findings were consistent with the biological mechanism (progesterone receptor expression in meningiomas) and aligned with earlier research
• The study was conducted with sufficient statistical power and methodological rigor to be considered highly credible by the scientific community

The BMJ study was the catalyst that transformed the Depo-Provera meningioma issue from an emerging concern into a major public health and legal matter.

2024-2025: Lawsuits Filed and MDL Proposed

Following the BMJ publication, lawsuits began filing at an accelerating pace:

• Individual plaintiffs filed lawsuits in federal courts across the United States alleging that Pfizer failed to warn about the meningioma risk
• Plaintiffs’ attorneys petitioned the Judicial Panel on Multidistrict Litigation (JPML) to consolidate the cases into an MDL
• The JPML granted consolidation, creating the Depo-Provera MDL for coordinated pretrial proceedings
• By the end of 2025, the case count had grown to thousands of individual lawsuits

December 2025: FDA Updates Depo-Provera Label

In a pivotal move, the FDA mandated a label update for Depo-Provera and Depo-SubQ Provera 104. The updated label now includes:

• An explicit warning that use of DMPA has been associated with an increased risk of meningioma
• Information referencing the epidemiological evidence supporting the association
• Guidance that healthcare providers should consider the meningioma risk when prescribing DMPA

The timing is significant: this label change came more than 30 years after Depo-Provera’s initial approval and years after the scientific evidence had accumulated. Plaintiffs in the litigation point to this delay as evidence that Pfizer failed in its duty to warn — the risk was knowable long before the FDA acted, and Pfizer did not voluntarily update its labeling.

2026: Litigation Milestones

The current year marks several critical milestones in the litigation:

Early 2026: Case Count Exceeds 3,000

The MDL has grown to more than 3,000 individual cases, with new cases continuing to file. Discovery — the exchange of evidence between plaintiffs and Pfizer — is well underway, including production of internal corporate documents and depositions of key Pfizer personnel.

May 2026: Rule 702 Hearings

Rule 702 hearings are scheduled for May 2026. These hearings will determine whether expert witnesses on both sides meet the standards for admissibility. For plaintiffs, surviving this challenge means the court finds their causation opinions scientifically reliable — a critical step toward trial.

December 2026: Pilot Trial

The first pilot trial is targeted for December 2026. This will be the first time a jury evaluates a Depo-Provera meningioma case, including the evidence of causation, failure to warn, and damages. The outcome will heavily influence the trajectory of settlement negotiations.

Why This Timeline Matters for Your Case

The chronological record serves several important functions in the litigation:

It Establishes What Pfizer Knew and When

Internal corporate documents — being produced through discovery — may reveal what Pfizer’s own scientists knew about the meningioma risk, when they knew it, and what decisions were made about labeling. If Pfizer had internal data or awareness of the risk and chose not to update its label, this strengthens failure-to-warn claims.

It Supports the Discovery Rule

For claimants who used Depo-Provera years ago, the timeline demonstrates that the connection between DMPA and meningioma was not publicly known until the BMJ study and FDA label update. This supports the discovery rule argument that the statute of limitations did not begin running until these events occurred.

It Shows a Pattern

The history of delayed warnings in pharmaceutical products is well-documented across multiple mass torts. The Depo-Provera timeline follows a familiar pattern: early signals, accumulating evidence, regulatory delay, and eventual acknowledgment — often decades after patients were first harmed.

Frequently Asked Questions

Why did it take so long for the FDA to add a meningioma warning?

The FDA’s regulatory process relies heavily on manufacturers to monitor their products and submit safety data. When manufacturers do not proactively disclose emerging risks, the FDA may not act until external research forces the issue. Plaintiffs argue that Pfizer should have updated its labeling voluntarily long before the FDA mandated it.

Does the FDA label change prove that Depo-Provera causes meningioma?

The FDA label change states that DMPA use is “associated with” an increased risk of meningioma. In regulatory language, this stops short of declaring definitive causation but acknowledges that the association is strong enough to warrant a formal warning. In the litigation, the label change is powerful evidence supporting plaintiffs’ causation claims.

Were there any earlier FDA warnings about Depo-Provera?

Depo-Provera has carried a boxed warning about bone density loss (osteoporosis risk) since 2004. However, no warning about meningioma risk was included until December 2025.

How does the French regulatory action relate to the U.S. litigation?

The French actions regarding progestins and meningiomas demonstrate that the risk was recognized by international regulators years before the FDA acted. Plaintiffs may use the French regulatory record as evidence that the meningioma risk was foreseeable and that Pfizer should have taken action earlier.

Is new research still being published?

Yes. The Depo-Provera/meningioma link continues to be an active area of research. Additional studies are expected to be published, which will further develop the scientific record and potentially strengthen plaintiffs’ claims.

Take the Next Step

The timeline of evidence, regulatory delay, and litigation milestones tells a clear story: the risk of meningioma from Depo-Provera was knowable long before patients were warned. If you or a loved one used Depo-Provera and developed a meningioma, the legal system is now providing a path to accountability.

If you’ve been affected, request a free case review today.

Advertisement. This content is provided for informational purposes only and does not constitute legal advice. NuLegal | Ashkaan Hassan, Esq. | CA Bar #283629